Turkish Abstract Abstract PDF Similar Articles Mail to Author

¹M.D. Asistant Professor, Başkent Üniversity Hospital in İstanbul, Department of Ophthalmology İstanbul/TURKEY
²M.D., Başkent Üniversity Hospital in İstanbul, Department of Ophthalmology, İstanbul/TURKEY
³M.D. Professor, Başkent Üniversity Hospital in Ankara, Department of Ophthalmology Ankara/TURKEY Glaucoma is a group of diseases with progressive optic disk and /or visual fields changes. The mainstay of current therapies (medical, laser, surgery) are focused of lowering intraocular pressure (IOP). The problems and failures with such therapies and the studies on physiopathology and genetics of glaucoma started explorations for new therapeutic modalities. Advances in our understanding of the genetic basis of glaucoma include the discovery of 14 linked sites (GLC 1A through GLC 1N) in primary open-angle glaucoma with three genes identified at these loci: myocilin, optineurin, and WDR 36. In the secondary glaucomas such as pseudoexfoliation syndromes, LOXL1 gene polymorphisms have been identified. Gene therapy can be used to replace a mutated gene that causes disease with a healthy copy of the gene, to inactivate or wipe out the aberrant gene that is responsible for the disease. This therapy can also be used to add or remove genes that are indirectly related to the pathophysiology of the disease. Ocular gene therapy can also provide the advantage of delivery of genes that express therapeutic proteins in a localized and sustained way. Gene therapy studies for the treatment of glaucoma are focused on lowering intraocular pressure and neuroprotection. An ideal gene delivery system is one that is able to efficiently deliver the genes to the target tissue with specificity and safety. Both viral and nonviral vector delivery systems have been tested in the animal eyes. The target tissues of gene therapy are trabecular meshwork, ciliary body, ciliary muscle, retina and optic disk. Keywords : Glaucoma, gene therapy, vector